EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access

Clonal Hematopoiesis Prevalence Years Before a Thyroid Cancer Diagnosis: A Case-Control Study

Paloma L Cabral iD, Nikhila Aimalla, Kyle Shoger, John R Caskey iD, Luke Zurbriggen, Neepa Shah, Ahmad Basharat, Luke F Moat, Erica Reinig, Kristin Long, Paola Pozzo, Terrie Kitchner und 3 weitere

JCO Precision Oncology · 2025-08 · (9)

DOI: 10.1200/po-24-00760 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift JCO Precision Oncology, 2025-08. Verfasst von Paloma L Cabral und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Clonal Hematopoiesis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Individuals with thyroid cancer have the highest prevalence of clonal hematopoiesis (CH) among patients with cancer. We sought to determine whether individuals who later develop thyroid cancer more frequently have CH before diagnosis or germline cancer susceptibility than healthy controls. METHODS We conducted a retrospective case-control study using subjects enrolled between 2002 and 2015 in a population-based biobank. Cases were healthy at enrollment but subsequently developed an incident thyroid cancer. Controls were healthy age- and race-matched subjects who were never diagnosed with a cancer. To assess baseline CH, whole-exome sequencing (WES) was performed on peripheral blood (PB) DNAs collected at enrollment. To assess CH acquisition over time, we recontacted a subset of cases and controls approximately 20 years after initial sampling for repeat PB WES. RESULTS At enrollment, on average 9 years before a thyroid cancer diagnosis for cases, we identified CH in three of 63 (5%) cases and four of 125 (3%) controls. Adjusting for age, sex, and race, those with CH had a 1.51 odds (0.31-7.33; P = .61) of a thyroid cancer diagnosis versus those without CH at baseline. We detected pathogenic germline cancer susceptibility variants in 11% of cases and 7% of controls ( P = .44). Among seven cases and seven controls recontacted, we found incident CH development in three (43%) and two (29%), respectively. CONCLUSION We found that individuals who later develop early-stage thyroid cancers do not have a significantly higher prevalence of CH years before their diagnosis nor carry germline cancer susceptibility variants more often than those who do not develop thyroid cancer. Larger longitudinal studies are needed to fully elucidate the impact of germline and exposures in CH etiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsClonal HematopoiesisHumansCase-Control StudiesMaleFemaleMiddle AgedRetrospective StudiesAdultPrevalenceAgedExome Sequencing

Autor:innen und Institutionen

  • Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Center for Precision Medicine Research, Marshfield Clinic Research Institute, Marshfield Clinic Health System, Marshfield, WI.
  • Department of Pathology, University of Wisconsin-Madison, Madison, WI.
  • Division of Endocrine Surgery, Department of Surgery, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.
  • Department of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI.

ORCID-Profile: Paloma L Cabral, John R Caskey, Tonia C Carter, Jane E Churpek

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Cabral, P. L., Aimalla, N., Shoger, K., Caskey, J. R., Zurbriggen, L., Shah, N., Basharat, A., Moat, L. F., Reinig, E., Long, K., Pozzo, P., Kitchner, T., Eickhoff, J., Carter, T. C., & Churpek, J. E. (2025). Clonal Hematopoiesis Prevalence Years Before a Thyroid Cancer Diagnosis: A Case-Control Study. JCO Precision Oncology. https://doi.org/10.1200/po-24-00760

Vancouver

Cabral PL, Aimalla N, Shoger K, Caskey JR, Zurbriggen L, Shah N, et al. Clonal Hematopoiesis Prevalence Years Before a Thyroid Cancer Diagnosis: A Case-Control Study. JCO Precision Oncology. 2025. doi:10.1200/po-24-00760

BibTeX
@article{Cabral2025,
  author = {Cabral, Paloma L and Aimalla, Nikhila and Shoger, Kyle and Caskey, John R and Zurbriggen, Luke and Shah, Neepa and Basharat, Ahmad and Moat, Luke F and Reinig, Erica and Long, Kristin and Pozzo, Paola and Kitchner, Terrie and Eickhoff, Jens and Carter, Tonia C and Churpek, Jane E},
  title = {Clonal Hematopoiesis Prevalence Years Before a Thyroid Cancer Diagnosis: A Case-Control Study},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-24-00760}
}
Kostenlos starten →